Stay updated on BMN 110 Phase 3B in Australian Patients Clinical Trial

Sign up to get notified when there's something new on the BMN 110 Phase 3B in Australian Patients Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BMN 110 Phase 3B in Australian Patients Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:22:17.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the dose of BMN 110 to 2.0 mg/kg/week in the Phase 3B open label study for Australian patients with MPS IVA, aiming to evaluate safety, tolerability, and various efficacy endpoints.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:41.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals diagnosed with MPS IVA confirmed by a GALNS enzymatic test, among other health-related conditions. Previously, this section had no information provided.
    Difference
    14%
    Check dated 2024-05-22T20:26:27.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:27:46.000Z thumbnail image

Stay in the know with updates to BMN 110 Phase 3B in Australian Patients Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BMN 110 Phase 3B in Australian Patients Clinical Trial page.